Novocure to Present Clinical Trial Designs and Preclinical Data on
Tumor Treating Fields at the 16th World Conference on Lung Cancer

September 04, 2015 10:24 AM Eastern Daylight Time

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure, a commercial stage oncology company, announced today that its
ongoing and future clinical trial designs in lung cancer will be
presented at the 16th World Conference on Lung Cancer (WCLC).
The WCLC is the world’s largest meeting dedicated to lung cancer and
other thoracic malignancies, organized by the International Association
for the Study of Lung Cancer (IASLC). The meeting will take place in
Denver, Colorado from September 6 to 9, 2015.

The data presented will include a preclinical background and the
clinical trial design of the following studies testing Tumor Treating
Fields (TTFields) in thoracic tumors:

STELLAR – an ongoing phase II pilot trial of TTFields together
with pemetrexed combined with cisplatin or carboplatin in malignant
pleural mesothelioma;

“The preclinical research and clinical research available to date
demonstrates that TTFields’ mechanism of action affects fundamental
aspects of cell division and could potentially have broad applicability
across a variety of solid tumors,” said Minesh Mehta, MD, Medical
Director of the Maryland Proton Treatment Center and a radiation
oncologist at the University of Maryland. “I am pleased that this novel
modality, associated with few side effects to date, is being explored in
brain metastases with the METIS trial, as well as in primary lung cancer
and mesothelioma.”

“TTFields have already been demonstrated to be safe when applied to the
upper torso in a phase II pilot trial for advanced NSCLC,” said Giovanni
Luca Ceresoli, MD, Head of Pulmonary Oncology at the Humanitas Gavazzeni
Hospital in Bergamo, Italy. “After examining the compelling data
obtained through long-term basic research of TTFields in different
thoracic malignancies, we are happy to lead the research of this
regional therapy in mesothelioma as a part of the STELLAR trial.”

“Novocure has developed a pipeline strategy to advance TTFields through
phase II pilot and phase III pivotal clinical trials across multiple
solid tumor types,” said Uri Weinberg, MD, PhD, Novocure’s Vice
President for Research and Development. “In addition to ongoing trials
in pancreatic cancer, ovarian cancer and brain metastases, we are
committed to developing TTFields as a potential treatment modality for
thoracic tumors, which unfortunately cause the highest number of
cancer-related deaths worldwide.”

STELLAR: A Phase II Trial of TTFields with Chemotherapy for First
Line Treatment of Malignant MesotheliomaDate and Time:
Tuesday, September 8 from 9:30 AM – 5:00 PMLocation: Exhibit Hall
(Hall B+C)Poster: P2.08-013Session: Thymoma, Mesothelioma
and Other Thoracic Malignancies - Mesothelioma

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) therapy is delivered by a portable,
non-invasive medical device designed for continuous use by patients. In
vitro and in vivo studies have shown that TTFields therapy
slows and reverses tumor growth by inhibiting mitosis, the process by
which cells divide and replicate. TTFields therapy creates low
intensity, alternating electric fields within a tumor that exert
physical forces on electrically charged cellular components, preventing
the normal mitotic process and causing cancer cell death.

TTFields therapy is not approved for the treatment of brain metastases
and malignant mesothelioma. In the United States and Japan, TTFields
therapy is not approved for the treatment of NSCLC. The safety and
effectiveness of TTFields therapy in these indications has not been
established.

Approved Indications

The US FDA has approved the TTFields therapy delivery system, Optune
(previously known as the NovoTTF-100A System), for use as a treatment
for adult patients (22 years of age or older) with
histologically-confirmed GBM, following histologically or
radiologically-confirmed recurrence in the supra-tentorial region of the
brain after receiving chemotherapy. The device is intended to be used as
monotherapy, and is intended as an alternative to standard medical
therapy for GBM after surgical and radiation options have been
exhausted. Patients should only use Optune under the supervision of a
physician properly trained in use of the device. Full prescribing
information is available at www.optune.com/safety
or by calling toll free 1-855-281-9301.

In the European Union, Optune is intended for the treatment of patients
with newly diagnosed GBM, after surgery and radiotherapy with adjuvant
temozolomide, concomitant to maintenance temozolomide. The treatment is
intended for adult patients, 18 years of age or older, and should be
started more than 4 weeks after surgery and radiation therapy with
adjuvant temozolomide. Treatment may be given together with maintenance
temozolomide and after maintenance temozolomide is stopped.

In the European Union, Optune is also intended for the treatment of
patients with recurrent GBM who have progressed after surgery,
radiotherapy and temozolomide treatment for their primary disease. The
treatment is intended for adult patients, 18 years of age or older, and
should be started more than 4 weeks after the latest surgery, radiation
therapy or chemotherapy.

In Japan, Optune (the NovoTTF-100A System) is approved for the treatment
of adult patients with recurrent supra-tentorial glioblastoma after all
possible surgical and radiation therapy options have been exhausted.

About Novocure

Novocure is a private Jersey Isle oncology company pioneering a novel
therapy for solid tumors called TTFields. Novocure’s US operations are
based in Portsmouth, NH and New York, NY. Additionally, the company has
offices in Germany, Switzerland, and Japan and a research center in
Haifa, Israel. For additional information about the company, please
visit www.novocure.com
or follow us at www.twitter.com/novocure.